Astrazeneca Pharma gets permission for launching oral lung cancer drug
DSIJ Intelligence / 24 Jul 2017
On Friday, Astrazeneca Pharma India announced after market hours, that the company has received an order from Drug Controller General of India for launching Osimertinib Tablets 40 mg and 80 mg in India.
On Friday, Astrazeneca Pharma India announced after market hours, that the company has received an order from Drug Controller General of India for launching Osimertinib Tablets 40 mg and 80 mg in India.
The company’s drug is an oral anti-cancer drug for the management of lung cancer. It is specialised for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), whose disease has progressed on or after EGFR TKI therapy.
45 countries including US, EU, Japan, China and other Asian countries have approved this tablet.
At Rs 1,002.40, the stock was trading up by 3.83% on BSE at 0930. It opened at Rs 984. Its 52-week high and low stood at Rs 1,146 and Rs 905, respectively.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.